Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients

Patte, Catherine, Auperin, Anne, Gerrard, Mary, Michon, Jean, Pinkerton, Ross, Sposto, Richard, Weston, Claire, Raphael, Martine, Perkins, Sherrie L., McCarthy, Keith and Cairo, Mitchell S. (2007). Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients. In: Proceedings of the 45th Annual Meeting and Exhibition of the American Society of Hematology. 45th Annual Meeting and Exhibition of the American Society of Hematology, San Diego, CA, USA, (2773-2780). 6-9 Dec 2003. doi:10.1182/blood-2006-07-036673


Author Patte, Catherine
Auperin, Anne
Gerrard, Mary
Michon, Jean
Pinkerton, Ross
Sposto, Richard
Weston, Claire
Raphael, Martine
Perkins, Sherrie L.
McCarthy, Keith
Cairo, Mitchell S.
Title of paper Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients
Conference name 45th Annual Meeting and Exhibition of the American Society of Hematology
Conference location San Diego, CA, USA
Conference dates 6-9 Dec 2003
Proceedings title Proceedings of the 45th Annual Meeting and Exhibition of the American Society of Hematology   Check publisher's open access policy
Journal name Blood   Check publisher's open access policy
Place of Publication Washington, D.C. , United States
Publisher American Society of Hematology
Publication Year 2007
Sub-type Fully published paper
DOI 10.1182/blood-2006-07-036673
ISSN 0006-4971
Volume 109
Issue 7
Start page 2773
End page 2780
Total pages 8
Language eng
Formatted Abstract/Summary
A previous study (LMB89) of the French Society of Pediatric Oncology for childhood mature B-cell lymphoma (B-NHL) demonstrated a 92% 3-year event-free survival (EFS) for intermediate-risk group B defined as “non-resected” stage I/II and CNS-negative advanced-stage III/IV (70% of cases). We performed the FAB/LMB96 trial to assess the possibility of reducing treatment in children/adolescents with intermediate-risk B-NHL without jeopardizing survival. “Early responding” patients (tumor response > 20% at day 7) were randomized in a factorial design between 4 arms, 2 receiving half-dose of cyclophosphamide in the second induction course with cyclophosphamide, Oncovin (vincristine), prednisone, Adriamycin (doxorubicin), methotrexate (COPADM) and 2 not receiving the maintenance course M1. A total of 657 patients were randomized (May 1996 to June 2001) and 637 were analyzed. The analysis showed no significant effect of any of the treatment reductions on EFS and survival. The 4-year EFS was 93.4% and 90.9% in the groups with full-dose and half-dose of cyclophosphamide (RR = 1.3, P = .40) and 91.9% and 92.5% in the groups with and without M1 (RR = 1.01, P = .98). There was no interaction between the 2 treatment reductions or between each treatment reduction and LDH level or histologic subtypes (Burkitt/Burkitt-like or large B-cell). Children/adolescents with intermediate-risk B-NHL who have an early response and achieve a complete remission after the first consolidation course can be cured with a 4-course treatment with a total dose of only 3.3 g/m2 cyclophosphamide and 120 mg/m2 doxorubicin.
(Blood. 2007;109:2773-2780)
© 2007 by The American Society of Hematology
Subjects 1102 Cardiovascular Medicine and Haematology
Keyword B-cell lymphoma (B-NHL)
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ
Additional Notes Prepublished online as Blood First Edition Paper, November 28, 2006

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 155 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 184 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 14 Jan 2010, 23:11:53 EST by Simon Utteridge on behalf of Faculty Of Health Sciences